3.1
NICE has published technology appraisal guidance on temozolomide for the treatment of recurrent malignant glioma (brain cancer) and carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma, and a cancer service guideline on improving outcomes for people with brain and other central nervous system tumours.